Comparing the current results to its competitors, Urogen Pharma Ltd reported Revenue increase in the 2 quarter 2026 by 206.17 % year on year. The sales growth was above Urogen Pharma Ltd 's competitors' average revenue growth of 5.07 %, achieved in the same quarter.
Urogen Pharma Ltd , slower than the average decrease reported by the company's competitors of -35.9 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -35.9 %
February 17, 2025
Navigating the Tumultuous Waters of Biotech: UroGen’s Resilience and Innovation Amidst Market Challenges In the dynamic and rapidly evolving world of biotechnology, the journey from research and development to commercialisation is fraught with challenges and opportunities alike. UroGen Pharma Ltd. a leading player in the realm of urothelial and specialty cancer treatments, has recently unveiled intriguing findings from its pivotal ENVISION trial. Even amidst market volatility, the company’s innovative spirit remains undeterred, offering potential breakthroughs in the treatment of bladder cancer. Decoding the Results of the ENVISION Trial Based in Princeton, New Jersey, UroGen Pharma Ltd. has focused its ...
October 2, 2024
In a significant milestone for bladder cancer treatment, UroGen Pharma Ltd. (Nasdaq: URGN) has announced the dosing of the first patient in its Phase 3 clinical trial for UGN-103, an innovative mitomycin-based formulation. This investigational drug is specifically tailored for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), a challenging condition that currently lacks optimal treatment options.Based in Princeton, N.J. UroGen Pharma is committed to developing cutting-edge solutions for urothelial and specialty cancers. UGN-103, administered as an intravesical solution, represents a new frontier in bladder cancer therapy. This next-generation formulation aims to e...
May 4, 2024
New Study Shows Promising Results for JELMYTO as Treatment for Low-Grade Upper Tract Urothelial Cancer: Comparable Complete Response Rate and Lower Stricture Incidence Compared to OLYMPUS Pivotal TrialPrinceton, N.J. - UroGen Pharma Ltd. (Nasdaq: URGN), a pioneering biotech company focused on developing and commercializing innovative solutions for urothelial and specialty cancers, has unveiled the findings of a sub-analysis conducted on a real-world patient cohort review involving the use of JELMYTO (mitomycin) for pyelocalyceal solution. These results were presented at the American Urological Association Meeting 2024 in San Antonio, TX. The study showcases a stepwise approach to retrograde administration of...
Tempest Therapeutics Inc is a biotechnology company focused on developing small molecule therapeutics to treat cancer and other diseases. Their business model revolves around identifying novel targets within the immune system and designing drugs that modulate these targets to enhance the body's immune response against cancer cells. Through strategic collaborations and partnerships, they aim to accelerate the development and commercialization of their product candidates.
Sources:
Urogen Pharma Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Urogen Pharma Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
